Impact of Brokerage Rating on Zimmer Biomet Holdings, Inc.(ZBH)

Many Zimmer Biomet Holdings, Inc.(ZBH) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Reiterated by RBC Capital Mkts on Feb 1, 2017 to Outperform, Raises Price Target to $ 133 from a previous price target of $130 .Company shares were Reiterated by Needham on Jan 26, 2017 to Strong Buy, Raises Price Target to $ 151 from a previous price target of $148 .Zimmer Biomet Holdings Inc was Upgraded by Citigroup to Neutral on Nov 29, 2016.

Company has reported several Insider transactions to the SEC, on Feb 6, 2017, Chad F Phipps (Sr. VP/Gen Counsel/Secretary) sold 10,500 shares at 117.62 per share price.On Feb 6, 2017, Katarzyna Mazur-hofsaess (Pres., Eur., M. East & Afr.) sold 44,195 shares at 118.00 per share price.On Feb 6, 2017, David C Dvorak (President and CEO) sold 43,207 shares at 117.77 per share price.

Zimmer Biomet Holdings Inc Last issued its quarterly earnings results on Jan 31, 2017. The company reported $2.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $2.11. The company had revenue of $2013.10 million for the quarter, compared to analysts expectations of $2013.08 million. The companys revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.83 by 21 Brokerage Firm. 12 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 6 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH): According to 16 Analysts, The short term target price has been estimated at $ 135.31.The target price could deviate by a maximum of $9.84 from the forecast price. In the near term, the target price could hit a high of $155 and a low of $ 120.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) witnessed a decline in the market cap on Tuesday as its shares dropped 0.48% or 0.57 points. After the session commenced at $117.38, the stock reached the higher end at $117.75 while it hit a low of $116.68. With the volume soaring to 1,129,794 shares, the last trade was called at $117.18. The company has a 52-week high of $133.21. The company has a market cap of $23,471 million and there are 200,299,570 shares in outstanding. The 52-week low of the share price is $91.52.

Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.


Share this post

Leave a Reply